{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:21Z","timestamp":1790795961657,"version":"4.1.0"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"18","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T00:00:00Z","timestamp":1568505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-77"],"award-info":[{"award-number":["ANR-10-LABX-77"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004562","name":"Minist\u00e8re de l'Education Nationale, de l'Enseignement Superieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115854"],"award-info":[{"award-number":["115854"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2019,9,15]]},"abstract":"<jats:p>With no available licensed vaccines or therapies, the West African Ebola virus disease epidemic of 2014 to 2016 caused 11,310 deaths. Following this outbreak, the development of vaccines has been accelerated. Combining different vector-based vaccines as heterologous regimens could induce a durable immune response, assessed through antibody concentrations. Based on data from phase 1 trials in East Africa and Europe, the dynamics of the humoral immune response from 7\u2009days after the boost immunization onwards were modeled to estimate the durability of the response and understand its variability. Antibody production is maintained by a population of long-lived cells. Estimation suggests that half of these cells can persist for at least 5 years in humans. Differences in prime-boost vaccine regimens affect only the short-term immune response. Geographical differences in long-lived cell dynamics were inferred, with higher long-term antibody concentrations induced in European participants.<\/jats:p>","DOI":"10.1128\/jvi.00579-19","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T13:16:01Z","timestamp":1561122961000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation"],"prefix":"10.1128","volume":"93","author":[{"given":"Chlo\u00e9","family":"Pasin","sequence":"first","affiliation":[{"name":"INSERM U1219, University of Bordeaux, Bordeaux, France"},{"name":"INRIA SISTM team, Talence, France"},{"name":"Vaccine Research Institute, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Balelli","sequence":"additional","affiliation":[{"name":"INSERM U1219, University of Bordeaux, Bordeaux, France"},{"name":"INRIA SISTM team, Talence, France"},{"name":"Vaccine Research Institute, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Van Effelterre","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica N. V., Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viki","family":"Bockstal","sequence":"additional","affiliation":[{"name":"Janssen Vaccines &amp; Prevention B. V., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Solforosi","sequence":"additional","affiliation":[{"name":"Janssen Vaccines &amp; Prevention B. V., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Prague","sequence":"additional","affiliation":[{"name":"INSERM U1219, University of Bordeaux, Bordeaux, France"},{"name":"INRIA SISTM team, Talence, France"},{"name":"Vaccine Research Institute, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[{"name":"Janssen Vaccines &amp; Prevention B. V., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[{"name":"INSERM U1219, University of Bordeaux, Bordeaux, France"},{"name":"INRIA SISTM team, Talence, France"},{"name":"Vaccine Research Institute, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2016. Situation report. Ebola virus disease. 10 June 2016. https:\/\/www.who.int\/csr\/disease\/ebola\/situation-reports\/archive\/en\/."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4218"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264755"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.016"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.007"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00740-09"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0880"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192312"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20644"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz071"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz070"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.45.20960"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2129"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004582"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200409109"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)93009-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.089"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.06.012"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.02.005"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000605"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.008"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13070"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.069"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.01.011"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00177"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.10663-10669.2001"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1006\/jtbi.2003.3208"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.019"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01901-w"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit650"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2507"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000911"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-4-278"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd984"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/fn.74.1.F43"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.004"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.011"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.05.051"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.002"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066092"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830161018"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80541-5"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115723"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1886"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002418"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00912.x"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28350"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00630"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9469.2006.00536.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75429"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000442."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/597069"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2007.03.002"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2013.04.014"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2007.00812.x"},{"key":"e_1_3_3_57_2","unstructured":"Commenges D Jacqmin-Gadda H Proust C Guedj J. 2006. A Newton-like algorithm for likelihood maximization: the robust-variance scoring algorithm. arXiv 2006:0610402."},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1515\/1948-4690.1040"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.00579-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.00579-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T14:48:10Z","timestamp":1646491690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.00579-19"}},"subtitle":[],"editor":[{"given":"Mark T.","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,15]]},"references-count":57,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9,15]]}},"alternative-id":["10.1128\/JVI.00579-19"],"URL":"https:\/\/doi.org\/10.1128\/jvi.00579-19","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,15]]},"assertion":[{"value":"2019-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00579-19"}}